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Patients with hidradenitis suppurativa (HS) have a diminished quality of life (QoL), and pain being a 
major contributor to poor QoL
1, 2
. A recent study reported that pain was the only contributor for 
decreased QoL if the severity of disease was excluded
3
. Despite the immense impact of pain in 
patients with HS, there is lack of studies that more closely analyze the pain in these patients.  
 
This multicenter study was conducted in Finland. Patients who were diagnosed with HS at least 6 
months prior to the study period were retrospectively identified. Pain intensity and type were 
evaluated during the study visit using the visual analog scale (VAS) and painDETECT. The 
dermatological life quality index (DLQI) questionnaire and Beck’s depression inventory (BDI) were 
used to evaluate the patients’ QoL and the severity of depression. Methods are described in detail 
in Additional materials. 
 
92 patients were included in the study. Patient characteristics are presented in Table S1. In 
painDETECT, 31.5% of patients were defined as having suspicion of neuropathic pain (NeP, ‘NeP 
positive’), 41.3% as having no NeP(‘NeP negative’), and 27.2% were classified as having unclear 
results. (Table 1) Most patients reporting moderate to severe pain by VAS were also “’NeP 
positive’ (Table 1). The percentage of patients in different pain groups stratified by disease 
severity is described in Table 1. 
 
Patients reporting NeP had more psychiatric comorbidities (44.8%, n=13/29), such as depression 
and sleep disorders, compared with patients in the ‘pain negative’ (23.7%, n=9/38) or ‘pain 
unclear’ (24.0%, n=6/25) groups, but this finding was not statistically significant. No other 
differences were found between these groups in comorbidities. NeP negative group used less pain 
medication (Table S2). 
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DLQI and BDI scores were significantly lower in ‘NeP negative’ group compared to other 
painDETECT groups (Table 1). Of the 92 patients, 49 reported severe impairment in QoL, 
depression, or NeP (Figure 1).  
Despite the overall mild pain level reported by the HS patients, one third of our patients were 
found to be ’ NeP positive´’ using the PainDETECT-tool, which suggests they possibly suffer from 
NeP. In addition, many were classified as “unclear”, which may reflect the view that nociceptive 
and neuropathic pain could be seen as different points of the same continuum rather than 
different entities
4
. Anxiety and depression are known to be associated with both chronic pain and 
HS
5
. Although we found no differences in the diagnosed somatic comorbidities between 
painDETECT groups, a significantly higher BDI scores were seen among ‘NeP positive’ patients. 
When the coexistence of NeP and depression were analyzed in our patients, only slightly more 
than half of the patients with indicators of depression had suspicion of comorbid NeP (Figure 1). 
Our results further strengthen the findings that patients with HS suffer from pain and indicate that 
this HS-related pain may have elements of NeP. It is important that dermatologists assess the pain 
in patients with HS regularly and consult with other pain specialists to comprehensively treat their 
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BDI: Beck Depression Inventory  
DLQI: Dermatology Life Quality Index  
HS: hidradenitis suppurativa 
IHS4: International Hidradenitis Suppurativa Severity Score System 
NeP: neuropathic pain 
QoL: quality of life 
VAS: visual analog scale 
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Table 1. Distribution of Patients in Pain-VAS and PainDETECT Groups by Gender, Hurley Stage, and IHS4 Severity, BDI and DLQI Score. 























Total, n(%) 34 (37.0) 42 (45.7) 16 (17.4)  38 (41.3) 25 (27.2) 29 (31.5)  
Males 16 (39.0) 18 (43.9) 7 (17.1)  17 (41.5) 13 (31.7) 11 (26.8)  
Females 18 (35.3) 24 (47.1) 9 (17.6) 0.9326 21 (41.2) 12 (23.5) 18 (35.3) 0.5838 
         















II 20 (32.3) 30 (48.4) 12 (19.4)  23 (37.1) 17 (27.4) 22 (35.5)  
III 5 (35.7) 6 (42.9) 3 (21.4) 0.4399 6 (42.9) 3 (21.4) 5 (35.7) 0.4581 
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Moderate 10 (29.4) 18 (52.9) 6 (17.6)  13 (38.2) 6 (17.7) 15 (44.1)  
Severe 4 (18.2) 11 (50.0) 7 (31.8) 0.0212 6 (27.3) 10 (45.5) 6 (27.7) 0.0610 
         















13−18 4 (26.7) 7 (46.6) 4 (26.7)  7 (46.6) 4 (26.7) 4 (26.7)  
19−63 3 (25.0) 6 (50.0) 3 (25.0) 0.5674 1 (8.3) 1 (8.3) 10 (83.4) 0.0017 
         
         
Psychiatric 
comorbidity, n(%) 
    9 (23.7) 6 (24.0) 13 (44.8) 0.1259 




No pain (0−4 mm) 
     






Mild (5−44 mm)     17 (40.5) 12 (28.6) 13 (31.0)  
Moderate to severe 
(45−100 mm) 
    1 (6.3)  4 (25.0)  11 (68.7) 0.0016 
DLQI, mean (range) 3.03 (0-9) 8.76 (0-23) 13.69 (4-29) <0.001* 4.53 (0-16) 8.84 (1-23) 10.55 (0-29) 0.0001* 
BDI, mean (range) 6.68 (0-4.0) 9.26 (0-30) 13.06 (1-32) 0.0198* 6.84 (0-20) 7.68 (0-19) 12.86 (0-32) 0.0030* 
BDI, Becks Depression Inventory ; DLQI, Dermatology Life Quality Index; ; IHS4, International Hidradenitis Suppurativa Severity Score System; 




Fig 1. Number of patients with severe impairment in quality of life (DLQI >10), depression (BDI>12), or neuropathic pain (painDETECT >18). 
Forty-nine of 92 patients reported above indicated  changes in more than one of the parameters, and indicated changes in all of the  3 
parameters were present in in one-fifth (n=9) of these patients. BDI, Beck Depression Inventory; DLQI, Dermatology Life Quality Index. 
 
 
 

